Development of Key Technologies to Treat Aortic Aneurysms

主动脉瘤治疗关键技术进展

• 批准号: 104012
• 金额: $ 61.25万
• 依托单位: LOMBARD MEDICAL LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104012
• 关键词: Development; Key; Technologies; Treat; Aortic

This project targets the treatment of abdominal aortic aneurysms; a fatal pathology most common in men in their mid sixties. It combines the clinical and medical implant skills of Lombard Medical with Microport's expertise in medical device manufacturing technology. This progam will develop a minimally invasive implant that can be used in day-case aneurysm surgery. This will save money for healthcare system world-wide and allow patients to return home and to a normal life as rapidly as possible. By investing in unprecedented levels of manufacturing automation, the companies expect to be able to deliver this therapeutic benefit at no additional cost to healthcare providers. Day case surgery for aneurysms is currently experimental and minimally invasive implants to treat aneurysms are almost completely hand-made. This project aims to take dramatic steps in both clinical and manufacturing technology.

本项目针对腹主动脉瘤的治疗；这是一种致命的疾病，最常见于60多岁的男性。它将Lombard medical的临床和医疗植入技术与Microport在医疗设备制造技术方面的专业知识相结合。该项目将开发一种可用于日间动脉瘤手术的微创植入物。这将为世界各地的医疗保健系统节省资金，并使患者能够尽快回家并恢复正常生活。通过投资于前所未有的制造自动化水平，这些公司希望能够在不增加医疗保健提供者成本的情况下提供这种治疗效果。动脉瘤的日间手术目前还处于实验阶段，治疗动脉瘤的微创植入物几乎完全是手工制作的。该项目旨在在临床和制造技术方面取得重大进展。